CH 45: Drugs for DM Flashcards
function of the pancreas
secrete glucagon and insulin
cluster of cells responsible for endocrine function of the pancreas
islets of Langerhans
physiologic action of insulin
-promotes entry of glucose into cells
-provides storage of glucose, as glycogen in skeletal muscle and the liver
-inhibits breakdown of fat and glycogen
-increases protein synthesis and inhibits gluconeogenesis
hyperglycemic medications:
NSAIDs
Corticosteroids
Diuretics
hyperglycemic hormones:
epi
thyroid
GH
glucocorticoids
hypoglycemic drugs:
alcohol
ACE inhibitors
beta blockers
lithium
why can insulin not be given PO
GI tract destroys insulin
reasons for morning hyperglycemia in patients:
-waning insulin
-dawn phenomenon (4-8 am)
-somogyi phenomenon
antihyperglycemic drug used with insulin for DM
Pramlintide (Symlin)
labs for regular insulin
liver
urinalysis
thyroid
K
Ca
Mg
antidiabetic drugs: biguanide (metformin) adverse effects
flatulence
D/N
anorexia
abd pain
bitter and metallic taste
lactic acidosis
antidiabetic drugs: incretin mimetics (GLP-1 agonists) adverse effects
N/V/D
nervousness
injection site reactions
antibody formation
pancreatitis
CKD
thyroid tumors
antidiabetic drugs: Incretin enhancers (DPP-4 inhibitors) adverse effects
flulike symptoms
URI
back pain
hypoglycemia
hepatic impairment
anaphylaxis
pancreatitis
antidiabetic drugs: Meglitinides adverse effects
antidiabetic drugs: sulfonylureas adverse effects
N
heartburn
dizziness
HA
drowsiness
hypoglycemia
cholestatic jaundice
blood dyscasias
antidiabetic drugs: thiazolidinediones adverse effects
URI
myalgia
HA
edema
weight gain
hypoglycemia
cholestatic jaundice
blood dyscrasias
antidiabetic drugs: other possible adverse effects
confusion
agitation
hallucinations
female genital infections
UTI
nasopharyngitis
hypotension
CKD
hyperkalemia
hypoglycemia
Metformin (Biguanide) therapuetic effects
treatment of type 2 DM
Metformin (Biguanide) adverse effects
N/V/D
abd discomfort
metallic taste
anorexia
HA
dizziness
agitation
fatigue
Metformin (Biguanide) labs
false positive urinary ketones
Metformin (Biguanide) onset, peak, duration
onset = less than 1 hr
peak = 1-3 hr
duration = 12 -24 hr
MOA for thiazolidinediones
reduce blood glucose by decreasing insulin resistance and inhibiting hepatic gluconeogenesis
MOA of meglitinides
act by stimulating the release of insulin form pancreatic islet cells
MOA of incretion mimetics
activate receptor GLP-1 causing lower blood glucose by increasing secretion of insulin slowing absorption of glucose and reducing glucagon